Corneodesmosin as a potential target of oral squamous cell carcinoma.

OBJECTIVE: The relationship between oral squamous cell carcinoma (OSCC) and Corneodesmosin (CDSN) remains unclear. This study aims to explore the correlation between CDSN and the prognosis and survival time of patients with OSCC. METHODS: Bioinformatics were used to identify the hub role of CDSN in the OSCC. A total of 200 patients with OSCC were recruited. Clinical and follow-up data were recorded, and the expression level of CDSN was detected. Pearson chi-square test and Spearman correlation coefficient were used to analyze the relationship between prognosis and related parameters in patients with OSCC. Univariate and multivariate Logistic regression and Cox proportional risk regression were applied for further analysis, and receiver operating characteristic curve and survival curve of subjects were plotted. RESULTS: CDSN was identified as the most significant hub gene of the OSCC by the cytoHubba. By the comparative toxicogenomics database (CTD) analysis, there was strong relationship between the CDSN and mouth neoplasms, head and neck neoplasms, squamous cell carcinoma of head and neck. The OSCC patients with low expression level of CDSN have poor overall survival compared with the high expression level of CDSN (HR = 0.75, 95% confidence interval [95%CI]: 0.57-0.98, P = .036). Spearman correlation coefficient analysis showed that CDSN expression level was significantly correlated with prognosis (ρ = -0.528, P < .001). Multivariate Logistic regression analysis showed that poor prognosis (odds ratio [OR] = 0.096, 95%CI: 0.049-0.189, P < .001) was significantly associated with low expression of CDSN. Cox regression analysis showed that the survival time of OSCC patients was shorter when CDSN expression was low (HR = 0.588, 95%CI: 0.420-0.823, P = .002). Strong predictive value of CDSN for the OSCC survival time was obtained by the biological process (BP)-neural network and support vector machine (SVM). CONCLUSION: CDSN was significantly correlated with OSCC, and the shorter the survival time of patients with OSCC was, the worse the prognosis was.

3D printing and biocompatibility study of a new biodegradable occluder for cardiac defect.

OBJECTIVE: To fabricate a biodegradable occluder for heart defect using the three-dimensional (3D) printing technique and evaluate its biosafety in an animal model. METHODS: Occluder samples were made by 3D printing technique using the self-developed lactide-sanya methyl carbonate-glycolide (PLLA-TMC-GA) co-polymer or PLTG as the bio-material. The biocompatibility (cytological and hematological) of the materials was evaluated by cytotoxicity experiments, hemolysis test, dynamic blood clotting test, and platelet adhesion test. Finally, the histocompatibility of the occluder was evaluated by implantation in a rabbit model. RESULTS: Occluder samples were printed satisfactorily. Cytotoxicity assay showed no significant toxicity of PLTG in the cells. Hemolysis test showed less than 5% hemolysis rate of PLTG indicating only a mild effect on the red blood cells. The dynamic coagulation test showed poor activation of endogenous clotting factors. PLTG resulted in lower platelet activation compared to PLLA, as indicated by the platelet adhesion test. Finally, no obvious tissue damage or necrosis was seen in the in vivo implantation experiment. CONCLUSION: A new PLTG-based biodegradable occluder for heart defects with good biocompatibility can be manufactured by the 3D printing technique.